<p>Adverum Biotechnologies, Inc.（纳斯达克代码：ADVM - 获取免费报告）首席运营官 Peter Soparkar 于 12 月 5 日（星期五）购买了 50,000 股该公司的股票。该股票的平均购买成本为每股 4.22 美元，总交易额为 211,000.00 美元。收购后，首席运营官持有该公司 80,189 股股票，估值约为 338,397.58 美元。这笔交易代表了其持股比例的 165.62% 的增长。该交易已在向美国证券交易委员会（SEC）提交的法律文件中披露，相关文件可通过此链接获取。</p>
<h2>Adverum Biotechnologies 股票上涨 2.3%</h2>
<p>在周一的午盘交易中，纳斯达克 ADVM 的股票上涨了 0.10 美元，达到了 4.36 美元。该公司交易了 987,543 股，相比之下，其平均交易量为 447,123 股。该股票的 50 日简单移动平均为 4.41 美元，200 日简单移动平均为 3.35 美元。Adverum Biotechnologies, Inc.的 1 年最低价为 1.78 美元，1 年最高价为 6.12 美元。该公司的市值为 9626 万美元，市盈率为-0.51，贝塔值为 0.87。</p>
<p>Adverum Biotechnologies（纳斯达克：ADVM - 获取免费报告）最近于 11 月 12 日（星期三）公布了季度财报。这家生物技术公司报告本季度每股收益（EPS）为-2.03 美元，低于分析师一致预期的-1.80 美元，差距为 0.23 美元。分析师预计 Adverum Biotechnologies, Inc.在本财年的每股收益将为-4.92 美元。</p>
<h2>华尔街分析师预测增长</h2>
<p>几位股票分析师对该公司发布了报告。Weiss Ratings 在 10 月 8 日（星期三）的研究报告中重申了对 Adverum Biotechnologies 股票的 “卖出（d-）” 评级。Truist Financial 在 10 月 24 日（星期五）的研究报告中设定了 Adverum Biotechnologies 股票的目标价为 5.00 美元。Chardan Capital 在 10 月 27 日（星期一）的研究报告中将 Adverum Biotechnologies 的评级从 “强烈买入” 下调至 “持有”。Mizuho 在 10 月 29 日（星期三）的研究报告中设定了 Adverum Biotechnologies 的目标价为 5.50 美元。最后，HC Wainwright 在 11 月 17 日（星期一）的报告中重新发布了 “中性” 评级，并将 Adverum Biotechnologies 的目标价设定为 5.00 美元（之前为 30.00 美元）。一位分析师给予该股票 “买入” 评级，四位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，Adverum Biotechnologies 目前的共识评级为 “持有”，平均目标价为 10.50 美元。</p>
<p><strong>阅读我们对 Adverum Biotechnologies 的最新股票分析</strong></p>
<h2>Adverum Biotechnologies 的机构交易</h2>
<p>对冲基金和其他机构投资者最近增加或减少了对该公司的持股。BML Capital Management LLC 在第二季度将其在 Adverum Biotechnologies 的持股增加了 11.5%。BML Capital Management LLC 目前拥有 3,057,526 股该生物技术公司的股票，价值 6,574,000 美元，此前在上个季度又收购了 315,209 股。Pale Fire Capital SE 在第一季度将其在 Adverum Biotechnologies 的持股增加了 16.9%。Pale Fire Capital SE 目前拥有 368,267 股该生物技术公司的股票，价值 1,609,000 美元，此前在上个季度又收购了 53,113 股。Two Sigma Investments LP 在第三季度将其在 Adverum Biotechnologies 的持股增加了 372.7%。Two Sigma Investments LP 目前拥有 88,670 股该生物技术公司的股票，价值 402,000 美元，此前在此期间又购买了 69,913 股。Jane Street Group LLC 在第二季度收购了 Adverum Biotechnologies 的新头寸，价值约为 153,000 美元。最后，Invesco Ltd.在第一季度收购了 Adverum Biotechnologies 的新头寸，价值约为 218,000 美元。对冲基金和其他机构投资者持有该公司 48.17% 的股票。</p>
<h2>关于 Adverum Biotechnologies</h2>
<p>（获取免费报告）</p>
<p>Adverum Biotechnologies, Inc.是一家临床阶段公司，开发基因治疗产品候选药物以治疗眼科疾病。其主要产品候选药物是 ixoberogene soroparvovec（ADVM-022），这是一种用于治疗湿性年龄相关性黄斑变性和糖尿病性黄斑水肿的单次玻璃体内注射基因治疗候选药物，目前处于二期临床试验阶段。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票，胜过 Adverum Biotechnologies</li>
<li>基础材料股票投资</li>
<li>Dollar Tree 的激增和 Home Depot 的下滑对消费者健康的影响</li>
<li>百分比涨幅告诉投资者什么，以及为什么它们并没有告诉全部故事</li>
<li>2026 年最有可能拆分的三只股票</li>
<li>现在购买的三只沃伦·巴菲特股票</li>
<li>ChargePoint 的复苏故事：为什么这只电动车股票再次上涨</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QURWTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QURWTQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Adverum Biotechnologies 吗？</h2>
<p>在你考虑 Adverum Biotechnologies 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Adverum Biotechnologies 并不在名单上。</p>
<p>虽然 Adverum Biotechnologies 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Adverum生物科技

<p>Adverum 生物科技的首席运营官 Peter Soparkar 购买了 50,000 股公司股票，花费 211,000 美元，使他的持股增加了 165.62%。此次股票购买在 SEC 文件中披露。交易后，Soparkar 持有 80,189 股，价值约 338,398 美元。公司的股票上涨了 2.3%，至 4.36 美元。分析师对该股票的评级不一，普遍评级为 “持有”，平均目标价为 10.50 美元。机构投资者持有公司 48.17% 的股票</p>

<p>Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) COO Peter Soparkar bought 50,000 shares of the company's stock in a transaction dated Friday, December 5th. The stock was bought at an average cost of $4.22 per share, for a total transaction of $211,000.00. Following the acquisition, the chief operating officer owned 80,189 shares of the company's stock, valued at approximately $338,397.58. This trade represents a 165.62% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.</p>
<div class="lb-trans"><p>Adverum Biotechnologies, Inc.（纳斯达克代码：ADVM - 获取免费报告）首席运营官 Peter Soparkar 于 12 月 5 日（星期五）购买了 50,000 股该公司的股票。该股票的平均购买成本为每股 4.22 美元，总交易额为 211,000.00 美元。收购后，首席运营官持有该公司 80,189 股股票，估值约为 338,397.58 美元。这笔交易代表了其持股比例的 165.62% 的增长。该交易已在向美国证券交易委员会（SEC）提交的法律文件中披露，相关文件可通过此链接获取。</p>
</div><h2>Adverum Biotechnologies Stock Up 2.3%</h2>
<div class="lb-trans"><h2>Adverum Biotechnologies 股票上涨 2.3%</h2>
</div><p>Shares of NASDAQ ADVM traded up $0.10 during mid-day trading on Monday, hitting $4.36. 987,543 shares of the company were exchanged, compared to its average volume of 447,123. The stock has a 50 day simple moving average of $4.41 and a 200-day simple moving average of $3.35. Adverum Biotechnologies, Inc. has a 1-year low of $1.78 and a 1-year high of $6.12. The firm has a market cap of $96.26 million, a price-to-earnings ratio of -0.51 and a beta of 0.87.</p>
<div class="lb-trans"><p>在周一的午盘交易中，纳斯达克 ADVM 的股票上涨了 0.10 美元，达到了 4.36 美元。该公司交易了 987,543 股，相比之下，其平均交易量为 447,123 股。该股票的 50 日简单移动平均为 4.41 美元，200 日简单移动平均为 3.35 美元。Adverum Biotechnologies, Inc.的 1 年最低价为 1.78 美元，1 年最高价为 6.12 美元。该公司的市值为 9626 万美元，市盈率为-0.51，贝塔值为 0.87。</p>
</div><p>Adverum Biotechnologies (NASDAQ:ADVM - Get Free Report) last announced its quarterly earnings data on Wednesday, November 12th. The biotechnology company reported ($2.03) EPS for the quarter, missing analysts' consensus estimates of ($1.80) by ($0.23). Analysts anticipate that Adverum Biotechnologies, Inc. will post -4.92 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Adverum Biotechnologies（纳斯达克：ADVM - 获取免费报告）最近于 11 月 12 日（星期三）公布了季度财报。这家生物技术公司报告本季度每股收益（EPS）为-2.03 美元，低于分析师一致预期的-1.80 美元，差距为 0.23 美元。分析师预计 Adverum Biotechnologies, Inc.在本财年的每股收益将为-4.92 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several equities analysts have issued reports on the company. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Adverum Biotechnologies in a research report on Wednesday, October 8th. Truist Financial set a $5.00 price target on shares of Adverum Biotechnologies in a research report on Friday, October 24th. Chardan Capital downgraded Adverum Biotechnologies from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Monday, October 27th. Mizuho set a $5.50 target price on Adverum Biotechnologies in a research report on Wednesday, October 29th. Finally, HC Wainwright reissued a &#34;neutral&#34; rating and issued a $5.00 target price (down previously from $30.00) on shares of Adverum Biotechnologies in a report on Monday, November 17th. One analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Adverum Biotechnologies presently has a consensus rating of &#34;Hold&#34; and an average target price of $10.50.</p>
<div class="lb-trans"><p>几位股票分析师对该公司发布了报告。Weiss Ratings 在 10 月 8 日（星期三）的研究报告中重申了对 Adverum Biotechnologies 股票的 “卖出（d-）” 评级。Truist Financial 在 10 月 24 日（星期五）的研究报告中设定了 Adverum Biotechnologies 股票的目标价为 5.00 美元。Chardan Capital 在 10 月 27 日（星期一）的研究报告中将 Adverum Biotechnologies 的评级从 “强烈买入” 下调至 “持有”。Mizuho 在 10 月 29 日（星期三）的研究报告中设定了 Adverum Biotechnologies 的目标价为 5.50 美元。最后，HC Wainwright 在 11 月 17 日（星期一）的报告中重新发布了 “中性” 评级，并将 Adverum Biotechnologies 的目标价设定为 5.00 美元（之前为 30.00 美元）。一位分析师给予该股票 “买入” 评级，四位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，Adverum Biotechnologies 目前的共识评级为 “持有”，平均目标价为 10.50 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on Adverum Biotechnologies</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 Adverum Biotechnologies 的最新股票分析</strong></p>
</div><h2>Institutional Trading of Adverum Biotechnologies</h2>
<div class="lb-trans"><h2>Adverum Biotechnologies 的机构交易</h2>
</div><p>Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BML Capital Management LLC increased its stake in shares of Adverum Biotechnologies by 11.5% during the 2nd quarter. BML Capital Management LLC now owns 3,057,526 shares of the biotechnology company's stock valued at $6,574,000 after acquiring an additional 315,209 shares during the last quarter. Pale Fire Capital SE boosted its position in shares of Adverum Biotechnologies by 16.9% in the first quarter. Pale Fire Capital SE now owns 368,267 shares of the biotechnology company's stock worth $1,609,000 after acquiring an additional 53,113 shares during the last quarter. Two Sigma Investments LP grew its holdings in Adverum Biotechnologies by 372.7% in the third quarter. Two Sigma Investments LP now owns 88,670 shares of the biotechnology company's stock valued at $402,000 after purchasing an additional 69,913 shares during the period. Jane Street Group LLC acquired a new position in Adverum Biotechnologies during the second quarter worth approximately $153,000. Finally, Invesco Ltd. purchased a new position in Adverum Biotechnologies during the first quarter worth approximately $218,000. Hedge funds and other institutional investors own 48.17% of the company's stock.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近增加或减少了对该公司的持股。BML Capital Management LLC 在第二季度将其在 Adverum Biotechnologies 的持股增加了 11.5%。BML Capital Management LLC 目前拥有 3,057,526 股该生物技术公司的股票，价值 6,574,000 美元，此前在上个季度又收购了 315,209 股。Pale Fire Capital SE 在第一季度将其在 Adverum Biotechnologies 的持股增加了 16.9%。Pale Fire Capital SE 目前拥有 368,267 股该生物技术公司的股票，价值 1,609,000 美元，此前在上个季度又收购了 53,113 股。Two Sigma Investments LP 在第三季度将其在 Adverum Biotechnologies 的持股增加了 372.7%。Two Sigma Investments LP 目前拥有 88,670 股该生物技术公司的股票，价值 402,000 美元，此前在此期间又购买了 69,913 股。Jane Street Group LLC 在第二季度收购了 Adverum Biotechnologies 的新头寸，价值约为 153,000 美元。最后，Invesco Ltd.在第一季度收购了 Adverum Biotechnologies 的新头寸，价值约为 218,000 美元。对冲基金和其他机构投资者持有该公司 48.17% 的股票。</p>
</div><h2>About Adverum Biotechnologies</h2>
<div class="lb-trans"><h2>关于 Adverum Biotechnologies</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Adverum Biotechnologies, Inc, a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials.</p>
<div class="lb-trans"><p>Adverum Biotechnologies, Inc.是一家临床阶段公司，开发基因治疗产品候选药物以治疗眼科疾病。其主要产品候选药物是 ixoberogene soroparvovec（ADVM-022），这是一种用于治疗湿性年龄相关性黄斑变性和糖尿病性黄斑水肿的单次玻璃体内注射基因治疗候选药物，目前处于二期临床试验阶段。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Adverum Biotechnologies</li>
<li>Basic Materials Stocks Investing</li>
<li>What Dollar Tree’s Surge and Home Depot’s Slide Say About Consumer Health</li>
<li>What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story</li>
<li>3 Stocks Most Likely to Split in 2026</li>
<li>3 Warren Buffett Stocks to Buy Now</li>
<li>ChargePoint's Comeback Story: Why This EV Stock Is Charging Up Again</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Adverum Biotechnologies</li>
<li>基础材料股票投资</li>
<li>Dollar Tree 的激增和 Home Depot 的下滑对消费者健康的影响</li>
<li>百分比涨幅告诉投资者什么，以及为什么它们并没有告诉全部故事</li>
<li>2026 年最有可能拆分的三只股票</li>
<li>现在购买的三只沃伦·巴菲特股票</li>
<li>ChargePoint 的复苏故事：为什么这只电动车股票再次上涨</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QURWTQ" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=ADVM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Adverum Biotechnologies Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Adverum Biotechnologies 吗？</h2>
</div><p>Before you consider Adverum Biotechnologies, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Adverum Biotechnologies 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adverum Biotechnologies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Adverum Biotechnologies 并不在名单上。</p>
</div><p>While Adverum Biotechnologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Adverum Biotechnologies 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Adverum 生物科技（NASDAQ:ADVM）的首席运营官购买了价值 211,000 美元的股票